Hims & Hers Health, Inc. (HIMS)
| Market Cap | 11.65B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 164.40M |
| Shares Out | 223.83M |
| EPS (ttm) | 0.68 |
| PE Ratio | 76.32 |
| Forward PE | 63.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,951,042 |
| Open | 47.82 |
| Previous Close | 47.89 |
| Day's Range | 47.36 - 52.30 |
| 52-Week Range | 13.47 - 72.98 |
| Beta | 2.02 |
| Analysts | Hold |
| Price Target | 39.36 (-24.36%) |
| Earnings Date | Aug 4, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $39.36, which is a decrease of -24.36% from the latest price.
News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
HIMS COURT NOTICE: Hims & Hers Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by the August 25 Legal Deadline (NYSE:HIMS)
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's ...
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
LOS ANGELES , July 9, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) ...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Hims & Hers Announces Planned 2026 Expansion to Canada, Following ZAVA Acquisition Completion
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program ...
Oklo, NuScale, Hims Defy Trump Tariffs - And Power The Russell 2000 Toward New Highs
As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creat...
Hims & Hers Health: Unlocking A $6 Billion Future
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting reten...
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recen...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
Hims & Hers Can Still Thrive Without GLP-1s
Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership ...
Hims & Hers Health: Buy The Novo Nordisk Drama Dip
The Hims & Hers Health investment thesis remains intact, despite the Novo Nordisk partnership ending, due to not being focused on branded GLP-1s. The company has long-term business targets, including ...
Hims & Hers: You Are Missing The Big Picture
Novo Nordisk just killed the deal. But Hims might come out even stronger. Here's why the market got it wrong. GLP-1s are just the tip of the iceberg. Hims is quietly positioning itself as the gateway ...
HIMZ: Buy For Short-Term Gains On Hims & Hers Health, But Be Wary Of The Risks
HIMZ offers 2x leveraged exposure to HIMS, ideal for high-risk, short-term traders seeking amplified volatility, not long-term investors. Recent HIMS volatility, including the Novo Nordisk partnership...
Hims & Hers Health, Inc. (NYSE: HIMS) Accused of “Illegal Mass Compounding and Deceptive Marketing” Practices; Investors Urged to Contact Award-Winning Firm, Gibbs Mura
OAKLAND, Calif.--(BUSINESS WIRE)---- $HIMS #ClassAction--Gibbs Mura announces a class action lawsuit has been filed on behalf of Hims & Hers Health, Inc. investors.
Stocks on the Move: Hims & Hers Health and JetBlue
The Investment Committee discuss their strategy on some stocks on the move today.
Hims Won't Back Down From Selling Cheap Weight-Loss Shots
Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ending their distribution partnership over "deceptive marketing" practices. ...
HIMS SECURITIES: Lose Money on Hims & Hers Health, Inc. (NYSE:HIMS)? Contact BFA Law about the Pending Securities Fraud Investigation
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the...
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy, Faces Investor Scrutiny- Hagens Berman
SAN FRANCISCO , June 25, 2025 /PRNewswire/ -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it term...
After Its Biggest Drop Ever
HIMS just suffered the biggest single-day drop in its trading history
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Healt...
Hims & Hers: Panic Sell Or Opportunistic Buy?
The Hims & Hers and Novo Nordisk "long-term collaboration" has ended up in flames within a couple of months, causing steep declines in both stocks. In this report, we discuss the breakup and assess th...
Hims & Hers: Here are the risks with the stock after Novo Nordisk terminated its partnership
Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.
Johnson Fistel Investigates Hims & Hers Regulatory Evasion and Investor Impact
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) regarding possible violations of fe...
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth darling Hims & Hers Health Inc HIMS got slapped with a 34% stock crash on Monday. Novo Nordisk A/S NVO ended their relationship – and it wasn't amicable.